Dr. Kai He, MD, PHD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 60
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license 49048
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
- Ut Health San Antonio Multispecialty & Research Ho San Antonio, TX
Medical groups
- University of Texas Health Science Center at San Antonio (1,297 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 60
- Services billed
- 333
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 156 | 46 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 97 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 7 companies reported 28 payments worth $25,122 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $23,268 |
|---|---|
| Janssen Biotech, Inc. | $1,484 |
| Galvanize Therapeutics, Inc | $161 |
| Jazz Pharmaceuticals Inc. | $75.29 |
| Janssen Scientific Affairs, LLC | $67.46 |
| Servier Bioinnovation | $47.33 |
| Genentech USA, Inc. | $18.32 |
| Consulting Fee | $21,868 |
|---|---|
| Travel and Lodging | $2,055 |
| Food and Beverage | $1,199 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 14, 2025 | Consulting Fee | $12,918 |
| E.r. Squibb & Sons, L.l.c. Jan 27, 2025 | Consulting Fee | $3,800 |
| E.r. Squibb & Sons, L.l.c. Jan 27, 2025 | Consulting Fee | $3,800 |
| Janssen Biotech, Inc. Dec 11, 2025 | Consulting Fee RYBREVANT · Oncology | $1,350 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $1,167 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Oct 30, 2025 | Travel and Lodging travel to BOSTON, MA | $55.63 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $37.74 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $19.98 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $4,627,057 in research payments for these studies, mostly to the institutions running them.
- A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
Amgen Inc. - Study name not reported
Iovance Biotherapeutics, Inc. - A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvaluma…
Amgen Inc. - Phase 1b/2 platform study of select immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC)
Servier Bioinnovation - M19-345 - Study to Determine the Safety Tolerability Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metasta…
AbbVie Inc. - Study name not reported
Iovance Biotherapeutics, Inc. - NAUTIKA1 previously LCMC4
Genentech, Inc. - Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie Inc. · Active, not recruiting · NCT03821935 - A phase iii, randomized, open-label, multicenter study evaluating the efficacy and safety of divaras
Genentech, Inc. - Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics, Inc. · Active, not recruiting · NCT03785249
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.